vascular disease screening now and the future
play

Vascular Disease Screening Now and the Future Stella Vig Consultant Vascular and General Surgeon Croydon University Hospital Co Chair London Foot Network. London SCLN. NHS London CVS: Preventing Harm Global 17.9 million deaths worldwide

0 downloads 3 Views 822 KB Size Report
  1. Vascular Disease Screening Now and the Future Stella Vig Consultant Vascular and General Surgeon Croydon University Hospital Co Chair London Foot Network. London SCLN. NHS London

  2. CVS: Preventing Harm

  3. Global • 17.9 million deaths worldwide CVD • 31% of all deaths

  4. 6.8 million people with CVD

  5. NHS Long Term Plan

  6. NHS Long Term Plan 49k Strokes 31k MIs

  7. Vascular Disease Peripheral Arterial Disease Aortic Aneurysms

  8. Risk factors for PAD Odds ratio 1 2 3 4 Male gender (c.f. female) Age (per 10 years) Diabetes Smoking Hypertension Dyslipidaemia Hyperhomocysteinaemia Race (Asian/hispanic/black vs. white) C-reactive protein (CRP) Renal insufficiency Norgren L, Hiatt WR (eds) et al. Eur J Vasc Endovasc Surg 2007;33(Suppl. 1):S1-S75.

  9. CAPRIE/AGATHA: overlap between CAD, CVD and PAD CAD CVD 7.4% 29.9% 24.7% 3.3% 11.8% 3.8% CAD PAD 35% 19.2% 7% PAD 10% 7% 15% 6% CAD = coronary artery disease CVD = cerebrovascular disease PAD = peripheral artery disease CVD 20% Coccheri S. Eur Heart J 1998;19(Suppl): 227

  10. Prevalence of f polyv yvascular dis isease in in registries Patients Stroke and Stroke and Stroke Study (n) Stroke PAD CHD PAD CHD Polyvascular 18,843 815 1086 REACH 1 15.9% 67,888 5703 (10%) (16.6%) (2.8%) (1.6%) 722 7391 1387 CAPRIE 2,3 26.3% 19,000 627 (3.3%) (39.2%) (10.7%) (7.1%) 94 119 45 DETECT 4 34.3% 753 753 (12.5%) (15.8%) (6.0%) 349 433 852 SCALA 5 >50% 852 ? (acute) (41%) (50.8%) 165 186 1218 GetABI 6 67.2% 6880 468 (38.4%) (17.7%) (13.5%) (15.3) 1 Bhatt DL et al. JAMA 2006;295:180 – 189; 2 Morrell J Br.J.Cardiol 2007;14:supplement 3; 3 Coccheri S. Eur Heart J 1998;19(Suppl): 227 4 Leys D et al.Cerebrovasc Dis 2006;21:60 – 66; 5 Weimar C et al.J Neurol (in press); 6 Diehm C et al. Eur Heart J 2006;27:1743 – 1749

  11. QOF PAD 001.1 .1 PAD Register • Symptomatic (>60. only 20%) • Asymptomatic Reduced ankle brachial pressure index is an independent predictor of PAD cardiac and cerebrovascular morbidity and mortality and may help to identify patients who would benefit from secondary prevention

  12. Aneury rysmal Disease

  13. Who should be screened? • men aged 65 or over – AAAs are up to 6 times more common in men than women, and the risk of getting one goes up as you get older • people who smoke – if you smoke or used to smoke, you're up to 15 times more likely to get an AAA • people with high blood pressure – high blood pressure can double your risk of getting an AAA • people with a parent, sibling or child with an AAA – you're about 4 times more likely to get an AAA if a close relative has had one

  14. Foot Screening in Patients with Diabetes

  15. Who is at Risk? • Neuropathic prevalence 58% 1 (85%) 2 • Ischaemic 4 X non diabetic • Neuroischaemic • Structural abnormality 1 Harati Y. Diabetic peripheral neuropathy. In: Kominsky SJ, ed. Medical and surgical management of the diabetic foot. St. Louis: Mosby, 1994:73-85. 2 Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care 1990;13:513-21.

  16. Diabetic Foot Complications Ischaemia • Deformity • Corn and callous • Ulceration • Gangrene • Osteomyelitis • Amputation (15 -46%)

  17. Integrated Care Pathways Competent Screening Risk stratification QOF Diabetic Foot Protection Multidisciplinary Diabetic Team Foot Team National Diabetes Foot Ulcer Audit

  18. NICE Guidance • Any inpatient with diabetes should have a diabetic foot check • Patients with diabetic foot disease should be referred to a Multidisciplinary Foot Team • Waterlow scores, Pressure reporting….. Stop the red ……. • Nationally failing abysmally!

  19. • Pictures of catastrophes

  20. Mr/Mrs X Blood Tests Blood Pressure Measurement ECG ECHO ABPI USS Aorta Foot Check Neuropathy assessment

  21. Networked Care: Every ry Opportunity Counts

  22. Changing Roles • Extending Roles • Increased Training • Consider Skill Mix and Ambitions • Opportunities for Local Investment • Manchester Model for PAD Pods • St Thomas’ Haematology/Primary Care AF • Foot HCA Champions at St Heliers • Dialysis Foot Checks • Community Checks with Open Access • Increased use of Pharmacist Screeners/Advice • Chair side Atrial Fibrillation testing in Pod clinics

  23. Networked Care: Every ry Opportunity Counts

Recommend Documents


what is peripheral vascular
What is Peripheral Vascular Disease?

10/10/2015 Peripheral Vascular Disease Ganesh Muthappan, MD, FACC

history
History: Role of Hypoxia Inducible

3/11/2017 History: Role of Hypoxia Inducible Factor-1 in Pulmonary Vascular

screening trial
screening trial H.C. Andersen Jes

The Viborg Vascular (VIVA) randomised screening trial H.C. Andersen Jes

infectious disease screening and testing for donors of
Infectious Disease Screening and

Infectious Disease Screening and Testing for Donors of HCT/Ps FDA-ISCT

diabetic eye screening extended screening intervals
Diabetic Eye Screening Extended

Diabetic Eye Screening Extended Screening Intervals Public Health England

disclosures disclosures
Disclosures Disclosures No conflicts

6/22/2013 Mechanical Support of the Right Ventricle in Children with

pulmonary vascular changes in pulmonary vascular changes
Pulmonary Vascular Changes in

Pulmonary Vascular Changes in Pulmonary Vascular Changes in Heart Disease

vascular surgery headline
Vascular Surgery Headline Surgical

Vascular Surgery Headline Surgical Treatments of Swedish Heart &

modeling cardiovascular disease using canine models
Modeling Cardiovascular Disease Using

Modeling Cardiovascular Disease Using Canine Models Rodney A White, MD

outline
Outline Hematopoeitic stem cells

6 th International Conference on Neonatal Stem Cell-Based Therapy in Pulmonary

david b weiss md division head orthopaedic trauma
David B. Weiss, MD Division Head

David B. Weiss, MD Division Head Orthopaedic Trauma University of Virginia

4 24 2018
4/24/2018 Supervised Exercise Therapy

4/24/2018 Supervised Exercise Therapy for Peripheral Artery Disease (PAD)

autonomic and vascular assessments
Autonomic and Vascular Assessments : q

PC8B SYSTEM Wireless V.5 Autonomic and Vascular Assessments : q A new tool

gsk investor presentation
GSK Investor Presentation May 2019

GSK Investor Presentation May 2019 Krupali Engineering researcher Nashik,

may 9 11 2018 omaha ne 44th annual midwest pharmacy
May 9-11, 2018 Omaha, NE 44th Annual

May 9-11, 2018 Omaha, NE 44th Annual Midwest Pharmacy Residents Conference

vignette session c patient safety moderator deepa
Vignette Session C: Patient Safety

Vignette Session C: Patient Safety Moderator: Deepa Bhatnagar, MD Unknown

introduction
Introduction Antiplatelet drugs are

Introduction Antiplatelet drugs are widely used for the primary and secondary

therapeutics company
Therapeutics Company Cynata

A Next Generation Stem Cell Therapeutics Company Cynata Therapeutics Limited

emis group plc 2012 results presentation
EMIS Group plc 2012 results

Healthcare without boundaries EMIS Group plc 2012 results presentation Mike

poster presentation day 1 april 12 th 2019
Poster Presentation Day 1 (April 12 th

Poster Presentation Day 1 (April 12 th , 2019) Name Poster Title Code

advanced registered nurse practitioner wound amp ostomy
Advanced Registered Nurse

Kimberly D. Thomas, DNP, ARNP, CWCN-AP, COCN Advanced Registered Nurse

ekg amp vital signs training
EKG & Vital Signs Training for

EKG & Vital Signs Training for Clinical Research Coordinators CCI Nursing